BIO-TECHNE Corp vs Clear Secure Inc — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while Clear Secure Inc trades at $43.54 (market cap $4.44B). The key difference: BIO-TECHNE Corp is far larger — about 2.6× Clear Secure Inc's market cap, and Clear Secure Inc pays the higher dividend (1.33%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Clear Secure Inc for 19 Days on average.
| TECH | YOU | |
|---|---|---|
Market Cap | $11.36B | $4.44B |
Volume | 5,390,331 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $72.61 | $62.36 |
52-Week Low | $43.31 | $29.61 |
Typical Hold Time | 63 Days | 19 Days |
Enterprise Value | $11.39B | $3.59B |
Dividend Yield | 0.44% | 1.33% |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Clear Secure (YOU) trades at $42.58, up 2.6% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 27% revenue growth in Q2 2026, beating earnings estimates, and robust profitability metrics including 66.7% gross margin and 90.3% ROE. Recent partnership with CrowdStrike and corporate membership launch highlight growth initiatives.
The stock offers 44% upside to the $61.40 consensus target with analyst sentiment divided equally between Buy and Hold. Key risks include competitive pressures and execution of expansion plans. Strong cash flow generation and accelerating membership growth support the bullish case, though valuation multiples remain elevated.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →